897954-59-5

Basic information

• Product Name: 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene
• Synonyms: 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene
• CAS NO: 897954-59-5
• Molecular Weight: 279.561
• Mol File: 897954-59-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene(897954-59-5)
• EPA Substance Registry System: 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene(897954-59-5)

Safety Data

• Hazardous Substances Data: 897954-59-5(Hazardous Substances Data)

Upstream product

• 36865-41-5 3-bromopropanol methyl ether 
• 183802-98-4 5-bromo-2-chlorophenol 

Downstream Products

• 1802408-28-1 10-chloro-9-(3-methoxypropoxy)-6-(1-methylcyclopropyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid 
• 1802408-28-1 (+)-10-chloro-9-(3-methoxypropoxy)-6-(1-methylcyclopropyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid 
• 1802408-28-1 (-)-10-chloro-9-(3-methoxypropoxy)-6-(1-methylcyclopropyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid 

Relevant articles and documents

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF HEPATITIS B

The present invention discloses compounds according to Formula (I), wherein X, G, R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION

The disclosure includes compounds of Formula (I), wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.

NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.